| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3392170 | Transplant Immunology | 2012 | 6 Pages |
Modern immunosuppressive armamentarium inadequately controls the humoral arm of recipient immune response, which in turn plays a central role in the pathogenesis of chronic rejection, a major cause of late allograft failure.A consensus sequence has progressively emerged from the integration of both experimental and clinical data, in which the binding of circulating donor-specific antibodies to mismatched HLA molecules expressed by graft microvasculature leads to chronic inflammation and progressive tissue destruction.Recent data suggest however that beyond their role in antibody production, B cells are also endowed with critical, yet overlooked, antibody-independent functions. Their abilities to present antigens and drive lymphoid neogenesis within rejected organ place them at the center of immune regulation with the power to enhance or inhibit antigraft immunity.The key challenges for the next few years will be to learn how these conceptual progresses can be translated into innovative B cell-targeting therapies to improve long-term allograft outcome.
► Humoral response plays a central role in the pathogenesis of chronic rejection. ► Alloantibody binding to graft microvasculature leads to microvascular inflammation. ► B cells present alloantigens to T cells within the graft, which amplifies rejection. ► A local humoral response develops in intragraft tertiary lymphoid tissue. ► B cells can participate in allograft tolerance.
